<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-id journal-id-type="iso-abbrev">Virol. J</journal-id><journal-title-group><journal-title>Virology Journal</journal-title></journal-title-group><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7338124</article-id><article-id pub-id-type="publisher-id">1375</article-id><article-id pub-id-type="doi">10.1186/s12985-020-01375-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Heui Man</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Namjoo</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mi-Seon</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Chun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4562-5533</contrib-id><name><surname>Chung</surname><given-names>Yoon-Seok</given-names></name><address><email>rollstone93@korea.kr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.418967.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1763 8617</institution-id><institution>Division of Viral Diseases, Center for Laboratory Control of Infectious Diseases, </institution><institution>Korea Centers for Disease Control and Prevention, </institution></institution-wrap>Cheongju-si, South Korea </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>17</volume><elocation-id>94</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The emergence of influenza viruses resistant to anti-influenza drugs is a threat to global public health. The Korea Centers for Disease Control and Prevention operates the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS) to monitor epidemics of influenza and Severe Acute Respiratory Infection (SARI) to identify mutated influenza viruses affecting drug resistance, pathogenesis, and transmission.</p></sec><sec><title>Methods</title><p id="Par2">Oropharyngeal swab samples were collected from KINRESS and SARI during the 2018&#x02013;2019 season. The specimens confirmed influenza virus using real-time RT-PCR on inoculated MDCK cells. HA and NA sequences of the influenza viruses were analyzed for phylogeny and mutations. Neuraminidase inhibition and hemagglutination inhibition assays were utilized to characterize the isolates.</p></sec><sec><title>Results</title><p id="Par3">Two A(H1N1)pdm09 isolates harboring an H275Y substitution in the neuraminidase sequence were detected in patients with acute hematologic cancer. They had prolonged respiratory symptoms, with the virus present in the respiratory tract despite oseltamivir and peramivir treatment. Through the neuraminidase inhibition assay, both viruses were found to be resistant to oseltamivir and peramivir, but not to zanamivir. Although hemagglutinin and neuraminidase phylogenetic analyses suggested that the 2 A(H1N1)pdm09 isolates were not identical, their antigenicity was similar to that of the 2018&#x02013;19 influenza vaccine virus.</p></sec><sec><title>Conclusions</title><p id="Par4">Our data indicate the utility of monitoring influenza-infected immunocompromised patients in general hospitals for the early detection of emerging neuraminidase inhibitor-resistant viruses and maintaining continuous laboratory surveillance of patients with influenza-like illness in sentinel clinics to monitor the spread of such new variants. Finally, characterization of the virus can inform the risk assessment for future epidemics and pandemics caused by drug-resistant influenza viruses.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Influenza virus</kwd><kwd>Drug resistance</kwd><kwd>H275Y</kwd><kwd>Immunocompromised patients</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003669</institution-id><institution>Korea Centers for Disease Control and Prevention</institution></institution-wrap></funding-source><award-id>4834-303</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Heui Man</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par15">Neuraminidase inhibitors (NAIs) are globally utilized for the treatment and prevention of influenza types A and B infection [<xref ref-type="bibr" rid="CR1">1</xref>], which are stockpiled by some countries, including the Republic of Korea, against unexpected pandemics. NAIs suppress the action of neuraminidase (NA) on the surface of the virus to prevent the spread of progeny virus from infected cells [<xref ref-type="bibr" rid="CR2">2</xref>]. Oseltamivir and peramivir, the most commonly used drugs for patients with influenza-like illnesses in the Republic of Korea, help to relieve clinical symptoms within 2 days of symptom manifestation and shorten the virus-release period in the respiratory tract [<xref ref-type="bibr" rid="CR1">1</xref>]. Baloxavir, a cap-dependent endonuclease inhibitor, was also recently licensed in the United States, following Japan [<xref ref-type="bibr" rid="CR3">3</xref>]. However, since most recently detected type A influenza viruses harbor the resistance variation S31N in the matrix gene, the M2 proton-channel blockers amantadine and rimantadine are no longer clinically applied [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par16">The Korea Centers for Diseases Control and Prevention (KCDC) has operated the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS) to monitor epidemic features of influenza viruses and analyze virus characteristics, including drug resistance, since 2000. The KCDC carries out diagnostic testing for influenza viruses in respiratory specimens requested by general hospitals as a national standard laboratory. If a drug resistance mutation is found in the NA gene, the KINRESS attempts to isolate the virus and perform phenotypic analysis (NA inhibition assay). The typical drug-resistance substitutions in NA include H275Y, E119D/G, and Q136R for A(H1N1)pdm09; E119V, D151G/V/D, R224K, E276D, R292K, and N294S for A (H3N2); and G104E, E117A/D, H134Y, and R150K for B virus [<xref ref-type="bibr" rid="CR5">5</xref>], although additional single and combination mutations may also result in NAI drug resistance (World Health Organization (WHO)) [<xref ref-type="bibr" rid="CR6">6</xref>]. Flusurver provides genetic analysis tools for screening drug-resistance and variant mutations to facilitate genetic characterization of viruses [<xref ref-type="bibr" rid="CR7">7</xref>]. Fluorescence-based NA inhibition assays using the MUNANA substrate have been conducted to confirm drug-resistant virus phenotyping [<xref ref-type="bibr" rid="CR8">8</xref>]. NAI-resistant viruses were identified in cases in which influenza virus was continuously detected following NAI treatment of hospitalized, immunosuppressed patients, rather than in clinical outpatients [<xref ref-type="bibr" rid="CR9">9</xref>]. Here, drug-resistant A(H1N1)pdm09 viruses were detected via the KINRESS in patients with acute hematologic cancer not exhibiting recovery despite oseltamivir and peramivir administration; these were characterized genetically and antigenically following isolation.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Clinical specimen collection</title><p id="Par17">Oropharyngeal swab samples were collected from patients with influenza-like illness through the KINRESS and processed in the national standard laboratory. Swabs were stored in Viral Transport Media (BD, San Jose, CA, USA) until further analysis.</p></sec><sec id="Sec4"><title>Viral RNA extraction</title><p id="Par18">Viral RNA was extracted from 140&#x02009;&#x003bc;L of sample medium using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec5"><title>One-step multiplex real-time reverse transcription-polymerase chain reaction (RT-PCR)</title><p id="Par19">RT-PCR was carried out using the Agpath ID One-step RT-PCR system (Applied Biosystems, Foster City, CA, USA) [<xref ref-type="bibr" rid="CR10">10</xref>]. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> lists multiplex (A/B/IPC and H1/H3/IPC) primer and Taq-Man probe sets. The 20-&#x003bc;L reaction mixture contained 5&#x02009;&#x003bc;L of RNA template, 590&#x02009;nM primers, 140&#x02009;nM probe, 10&#x02009;&#x003bc;L of 2&#x000d7; reaction buffer, 0.8&#x02009;&#x003bc;L of enzyme mixture, and RNase-free water. RT-PCR was performed on the ABI 7500Fast instrument (Applied Biosystems) with thermocycler conditions for reverse transcription (50&#x02009;&#x000b0;C, 30&#x02009;min), hot start DNA Taq polymerase activation (95&#x02009;&#x000b0;C, 10&#x02009;min), followed by 40&#x02009;cycles of denaturation (95&#x02009;&#x000b0;C, 15&#x02009;s) and annealing/extension (55&#x02009;&#x000b0;C, 30&#x02009;s). Data acquisition and analysis of the real-time PCR assay were performed using SDS software Version 1.4 (Applied Biosystems).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Primer and probe sequence information to detect influenza virus type (A/B) and subtype (H1/H3)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Type/Subtype</th><th>Primer/probe</th><th>Sequence (5&#x02032;&#x02013;3&#x02032;)</th><th>Target (bp)</th></tr></thead><tbody><tr><td rowspan="3">A</td><td>Forward</td><td>AATCCTGTCACCTCTGACTAAGG</td><td rowspan="3"><p>Matrix</p><p>(98)</p></td></tr><tr><td>Reverse</td><td>CATTYTGGACAAAKCGTCTACG</td></tr><tr><td>Probe</td><td>FAM-TGCAGTCCTCGCTCAC-MGBNFQ</td></tr><tr><td rowspan="3">B</td><td>Forward</td><td>GAATGCTGTCAATGAATATTGAGGG</td><td rowspan="3"><p>Nucleoprotein</p><p>(77)</p></td></tr><tr><td>Reverse</td><td>CATTGAGTCATTCATCATCTTGAGTAGAT</td></tr><tr><td>Probe</td><td>VIC-TCCTTTGACATCTGCAT-MGBNFQ</td></tr><tr><td rowspan="3">H1</td><td>Forward</td><td>AACAATTCAACAGACACTGTAGACACAGT</td><td rowspan="3">Hemagglutinin (144)</td></tr><tr><td>Reverse</td><td>GGGCTACCCCTCTTAGTTTRCATAGTTT</td></tr><tr><td>Probe</td><td>FAM- ATGTAACAGTAACACACTCTGT-MGBNFQ</td></tr><tr><td rowspan="3">H3</td><td>Forward</td><td>GGAATGGTTTGTCATTGGGAAT</td><td rowspan="3">Hemagglutinin (95)</td></tr><tr><td>Reverse</td><td>AAGCTCAATAATGAGRTCAGATGCA</td></tr><tr><td>Probe</td><td>VIC-CTTCCATTTGGAGTRATRCA-MGBNFQ</td></tr><tr><td rowspan="3">IPC</td><td>Forward</td><td>AGATTTGGACCTGCGAGCG</td><td rowspan="3"><p><italic>GAPDH</italic></p><p>(65)</p></td></tr><tr><td>Reverse</td><td>GAGCGGCTGTCTCCACAAGT</td></tr><tr><td>Probe</td><td>Cy5-TTCTGACCTGAAGGCTCTGCGCG-BHQ</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Virus isolation in MDCK cell lines</title><p id="Par20">Madin-Darby canine kidney (MDCK, American Type Culture Collection, Manassas, VA, USA) cells were seeded at 10<sup>5</sup>/mL in T25 flasks with Dulbecco&#x02019;s modified Eagle medium (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (Hyclone) and 1% penicillin&#x02013;streptomycin (Sigma, St. Louis, MO, USA) in a final volume of 5&#x02009;mL and incubated at 37&#x02009;&#x000b0;C in a humidified atmosphere with 5% CO<sub>2</sub> for 48&#x02009;h. When the cells reached 90% confluence, the culture medium was discarded, and the cells were washed three times with warm phosphate-buffered saline. Then, 0.2&#x02009;mL of clinical specimen was added into a flask to allow the inoculum to adsorb (37&#x02009;&#x000b0;C, 60&#x02009;min). Medium (5&#x02009;mL) containing 2&#x02009;&#x003bc;L/mL TPCK-trypsin was added to the flask. The culture was observed daily for cytopathic and morphological changes using an inverted light microscope. The culture supernatant was harvested when 75&#x02013;100% of the infected cells showed cytopathic effect and stored at &#x02212;&#x02009;70&#x02009;&#x000b0;C [<xref ref-type="bibr" rid="CR11">11</xref>]. Finally, A/Korea/S0002/2019 and A/Korea/S0003/2019 A(H1N1)pdm09 viruses were isolated.</p></sec><sec id="Sec7"><title>Hemagglutinin (HA) and neuraminidase (NA) sequencing</title><p id="Par21">Viral RNA was extracted from oropharyngeal swab samples and their isolates using the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer&#x02019;s instructions. Reverse transcription was performed to obtain cDNA using the U12 primer, then the HA and NA genes were amplified with specific primers [<xref ref-type="bibr" rid="CR12">12</xref>]. The PCR products were purified using the QIAquick&#x02122; PCR Purification Kit (Qiagen) according to the manufacturer&#x02019;s instructions and subjected to direct sequencing using the Big Dye Terminator V.3.0&#x02009;Cycle Sequencing Ready Reaction Kit (Applied Biosystems) together with primers for each PCR fragment (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) on the ABI 3130xl Genetic Analyzer automatic sequencer (Applied Biosystems). The nucleotide sequences were edited, assembled, and aligned using MEGA X 10.1 software (<ext-link ext-link-type="uri" xlink:href="https://www.megasoftware.net/">https://www.megasoftware.net/</ext-link>). The complete HA (GISAID: EPI1602907 and EPI1602905) and NA (GISAID: EPI1602908 and EPI1602906) sequences were obtained from the 2 A(H1N1)pdm09 viruses.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Sequencing primers for HA and NA of A(H1N1)pdm09 virus</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Primers (F/R)</th><th>Gene (subtype)</th><th>Locus</th><th>Sequence (5&#x02032;&#x02013;3&#x02032;)</th></tr></thead><tbody><tr><td>A-uni-HA-1F</td><td>HA</td><td>1&#x02013;28</td><td>TATTCGTCTCAGGGAGCAAAAGCAGGGG</td></tr><tr><td>HA-H1-345F</td><td>HA (H1)</td><td>345&#x02013;365</td><td>GGAACGTGTTACCCAGGAGAT</td></tr><tr><td>HA-H1-680F</td><td>HA (H1)</td><td>680&#x02013;701</td><td>TCAAGCCGGAAATAGCAATAAG</td></tr><tr><td>HA-H1-1137F</td><td>HA (H1)</td><td>1137&#x02013;1156</td><td>AGCCGACCTGAAGAGCACAC</td></tr><tr><td>HA-H1-714R</td><td>HA (H1)</td><td>691&#x02013;714</td><td>CCTCACTTTGGGTCTTATTGCTAT</td></tr><tr><td>HA-H1-1093R</td><td>HA (H1)</td><td>1072&#x02013;1093</td><td>CATCCATCTACCATCCCTGTCC</td></tr><tr><td>HA-H1-1330R</td><td>HA (H1)</td><td>1309&#x02013;1330</td><td>GCATTGTAAGTCCAAATGTCCA</td></tr><tr><td>A-uni-HA-1807R</td><td>HA</td><td>1773&#x02013;1807</td><td>ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT</td></tr><tr><td>A-uni-NA-1F</td><td>NA</td><td>1&#x02013;29</td><td>TATTGGTCTCAGGGAGCAAAAGCAGGAGT</td></tr><tr><td>H1-NA-324F</td><td>NA (N1)</td><td>324&#x02013;345</td><td>GGTTCCAAGGGGGATGTGTTTG</td></tr><tr><td>H1-NA-744F</td><td>NA (N1)</td><td>744&#x02013;766</td><td>TGGACAGGCCTCATACAAGATCT</td></tr><tr><td>H1-NA-645R</td><td>NA (N1)</td><td>622&#x02013;645</td><td>AGTGTCTGTTATTATTCCGTTGTA</td></tr><tr><td>H1-NA-1010F</td><td>NA (N1)</td><td>985&#x02013;1010</td><td>CAGTATCGTCTAATGGAGCAAATGGA</td></tr><tr><td>H1-NA-1057R</td><td>NA (N1)</td><td>1036&#x02013;1057</td><td>CTATCCAAACACCATTGCCGTA</td></tr><tr><td>A-uni-NA-1442R</td><td>NA</td><td>1407&#x02013;1442</td><td>ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Genetic characterization</title><p id="Par22">Genetic screening for drug resistance in the NA gene and mutational analysis of the HA and NA genes were conducted using Flusurver (<ext-link ext-link-type="uri" xlink:href="https://flusurver.bii.a-star.edu.sg/">https://flusurver.bii.a-star.edu.sg/</ext-link>), last updated on July 26, 2019. Phylogenies were reconstructed using the neighbor-joining method and bootstrapped 1000 times with MEGA X 10.1 using HA- or NA-aligned DNA sequences of the A(H1N1)pdm09 reference vaccine [<xref ref-type="bibr" rid="CR13">13</xref>] and other isolates from the Republic of Korea.</p></sec><sec id="Sec9"><title>NA inhibition assay</title><p id="Par23">A fluorescence-based neuraminidase inhibition assay was conducted using the NA-Fluor&#x02122; Influenza Neuraminidase Assay Kit (Applied Biosystems), according to the manufacturer&#x02019;s instructions. The susceptibility of influenza viruses to NAI was characterized using oseltamivir, zanamivir, and peramivir at concentrations that inhibited the NA activity by 50% (IC<sub>50</sub>) as described previously [<xref ref-type="bibr" rid="CR14">14</xref>]. As defined by the WHO, influenza A viruses with normal, reduced, and highly reduced NA activity inhibition exhibit a&#x02009;&#x0003c;&#x02009;10-fold, 10- to 100-fold, and&#x02009;&#x02265;&#x02009;100-fold increase in IC<sub>50</sub>, respectively; the last are considered clinically resistant [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec10"><title>Hemagglutination inhibition (HI) assay</title><p id="Par24">Assays were performed according to standard methods [<xref ref-type="bibr" rid="CR16">16</xref>]. Four HA units/25&#x02009;&#x003bc;L of A(H1N1)pdm09 virus were tested using 0.5% suspensions of turkey red blood cells. HI titers were reciprocals of the highest dilutions of sera that inhibited hemagglutination. Post-infection ferret antisera against 18&#x02013;19 and 19&#x02013;20 vaccine viruses were treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan).</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>A(H1N1)pdm09 detection and isolation in immunocompromised patients</title><p id="Par25">Influenza A virus was detected in oropharyngeal swab samples collected from patients with lymphoblastic leukemia (Patient A: female, 37&#x02009;years old) and relapsed lymphoma (Patient B: female, 38&#x02009;years old), with real-time RT-PCR Ct values of 28 and 29, respectively. A(H1N1)pdm09 viruses were identified by additional H1 subtype detection at respective Ct values of 28 and 29 (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Plaques were observed within 48&#x02009;h following specimen inoculation in MDCK cells, with the harvested supernatant exhibiting an HA titer of 256. The isolates were named A/Korea/S0002/2019 and A/Korea/S0003/2019.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>A(H1N1)pdm09 virus detection in immunocompromised patients by real-time RT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient</th><th colspan="5">Genetic detection using real-time RT-PCR</th></tr><tr><th>IFV A</th><th>IFV B</th><th>A/H1</th><th>A/H3</th><th>IPC</th></tr></thead><tbody><tr><td>A</td><td char="." align="char">26.1</td><td>UD<sup>*</sup></td><td>25.4</td><td>UD<sup>*</sup></td><td>26.3/26.2</td></tr><tr><td>B</td><td char="." align="char">27.0</td><td>UD<sup>*</sup></td><td>25.8</td><td>UD<sup>*</sup></td><td>32.1/34.0</td></tr></tbody></table><table-wrap-foot><p>UD<sup>*</sup>: undetected</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Genetic characterization</title><sec id="Sec14"><title>NA genetic analysis for screening drug resistance, phylogeny, and variation</title><p id="Par26">The sequences of the NA gene from oropharyngeal swab samples and the isolated viruses from each patient were determined and were found to have no mutations resulting from adaptation to the cell culture conditions. The H275Y NA substitution (N1 numbering), associated with strong drug resistance, was observed in (GISAID: EPI1602908 and EPI1602906) of A(H1N1)pdm09 isolates from both immunocompromised patients. Other NA drug-resistance substitutions (V116A, I117V, Q136K, D151A, Y155H, R156K, D198V, I222V, R224K, Q226H, E227D, E277Q, R293K, N294S, E425G, and I436N) were not detected. The NA sequences of A/Korea/S0002/2019 and A/Korea/S0003/2019 most closely matched with those of A/Brisbane/02/2018 (98.5 and 98.3% amino-acid identity, respectively). The viruses could be distinguished in the phylogenetic tree (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A/Korea/S0002/2019 had six amino acid differences (T13I, Q51K, F74S, H275Y, D416N, and T452I) relative to A/Brisbane/02/2018 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), while A/Korea/S0003/2019 had eight (T13I, I29M, P93S, I99V, H275Y, G298A, V321I, and V394I). Table <xref rid="Tab4" ref-type="table">4</xref> shows the amino acid substitutions in NA compared with A/Brisbane/02/2018 and their reported effects.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Phylogenetic tree of neuraminidase (NA) gene of drug resistant A(H1N1)pdm09. The H275Y mutated viruses (A/Korea/S0002/2019 and A/Korea/S0003/2019) were not identical in phylogenetic tree of NA. A/Korea/S0002/2019 harbored Q51K, F74S, T152I and D416N mutation and A/Korea/S0003/2019 harbored I29M, P93S, I99V, G298A, V321I and V394I mutation compared to A/Brisbane/02/2018</p></caption><graphic xlink:href="12985_2020_1375_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>NA genetic mutations compared with A/Brisbane/02/2018 (N1 numbering)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th>Amino acid identity with A/Brisbane/02/2018 (%)</th><th>T13I</th><th>I29M</th><th>Q51K</th><th>F74S</th><th>P93S<sup>a,b</sup></th><th>I99V<sup>b</sup></th><th>H275Y<sup><bold>c</bold></sup></th><th>G298A<sup>a</sup></th><th>V321I<sup>a</sup></th><th>V394I<sup>b</sup></th><th>D416N<sup>a,b</sup></th><th>T452I<sup>a,b,d</sup></th></tr></thead><tbody><tr><td>A/Korea/S0003/2019</td><td>98.3</td><td>&#x025cb;</td><td>&#x025cb;</td><td/><td/><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td/><td/></tr><tr><td>A/Korea/S0002/2019</td><td>98.5</td><td>&#x025cb;</td><td/><td>&#x025cb;</td><td>&#x025cb;</td><td/><td/><td>&#x025cb;</td><td/><td/><td/><td>&#x025cb;</td><td>&#x025cb;</td></tr><tr><td colspan="2">Frequency (%)</td><td>99.79</td><td>0.65</td><td>18.14</td><td>16.78</td><td>0.34</td><td>0.89</td><td>0.58</td><td>0.75</td><td>1.13</td><td>1.37</td><td>36.25</td><td>18.76</td></tr></tbody></table><table-wrap-foot><p>&#x025cb; substitution of the amino acid indicated</p><p><sup>a</sup>Binding small ligand</p><p><sup>b</sup>viral oligomerization interfaces</p><p><sup>c</sup>strong drug resistance</p><p><sup>d</sup>binding host protein</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>HA phylogeny and variation</title><p id="Par27">In the HA phylogenetic tree, two viruses belonged to clade 6B.1A, including A/Brisbane/02/2018 and a virus similar to a 2018&#x02013;2019 season-isolated A(H1N1)pdm09 in the Republic of Korea. A/Korea/S0002/2019 and A/Korea/S0003/2019 HA sequences best matched with those of A/Brisbane/02/2018 (98.6 and 98.9% amino-acid identity, respectively). The two viruses fell into different subclades according to discrepancies at residues 158, 202, 277, and 521. A/Korea/S0002/2019 belonged to subclade 6B.1A5 and A/Korea/S0003/2019 to subclade 6B.1A4 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> shows the amino-acid substitutions in the HA gene compared with A/Brisbane/02/2018 and their reported effects.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Phylogenetic tree of hemagglutinin (HA) gene of drug resistant A(H1N1)pdm09. A/Korea/S0002/2019 virus belonged to 6B.1A5 harboring T202I, N277D and K521R mutations compared to A/Brisbane/02/2018 and clustered with isolated viruses in 2019&#x02009;year, Republic of Korea (ROK), whereas A/Korea/S0003/2019 virus belonged to 6B.1A4 harboring A158E mutation and clustered with isolated viruses in previous year</p></caption><graphic xlink:href="12985_2020_1375_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>HA genetic variation compared with A/Brisbane/02/2018 (H1 numbering)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th>Amino acid identity with A/Brisbane/02/2018 (%)</th><th>G62R<sup>a,b,c</sup></th><th>N146D<sup>a,b,c</sup></th><th>A158E <sup>a,b,c</sup></th><th>T202I <sup>a,b,c</sup></th><th>R240Q <sup>a,c,d</sup></th><th>N277D<sup>b</sup></th><th>A299P<sup>a,b</sup></th><th>V315I<sup>a,b</sup></th><th>K521<sup>b</sup></th></tr></thead><tbody><tr><td>A/Korea/S0003/2019</td><td>98.94</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td/><td>&#x025cb;</td><td/><td>&#x025cb;</td><td>&#x025cb;</td><td/></tr><tr><td>A/Korea/S0002/2019</td><td>98.59</td><td>&#x025cb;</td><td>&#x025cb;</td><td/><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td><td>&#x025cb;</td></tr><tr><td colspan="2">Frequency (%)</td><td>84.19</td><td>17.76</td><td>0.97</td><td>19.77</td><td>99.87</td><td>29.46</td><td>84.85</td><td>85.38</td><td>3.08</td></tr></tbody></table><table-wrap-foot><p>&#x025cb; substitution of the amino acid indicated</p><p><sup>a</sup>Binding small ligand</p><p><sup>b</sup>viral oligomerization interfaces</p><p><sup>c</sup>antibody recognition sites</p><p><sup>d</sup>host cell receptor binding</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>NA inhibition assay</title><p id="Par28">A/Korea/S0003/2019 and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by oseltamivir and peramivir with &#x0003e;&#x02009;100 IC<sub>50</sub> fold-changes relative to drug-sensitive virus, but were normally susceptible to zanamivir (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>). However, every isolate collected from the KINRESS in 2018&#x02013;2019 was susceptible to all three drugs.
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Neuraminidase inhibition assay for A(H1N1)pdm09 viruses isolated in immunocompromised patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Virus</th><th rowspan="2">Type (Subtype)</th><th rowspan="2">Genotype</th><th colspan="3">NAI resistance (IC<sub>50</sub> fold change)</th></tr><tr><th>Oseltamivir</th><th>Zanamivir</th><th>Peramivir</th></tr></thead><tbody><tr><td>A/Korea/S0003/2019</td><td rowspan="2">A(H1N1)pdm09</td><td>Variant (H275Y)</td><td><p>HRI</p><p>179.33</p></td><td><p>NI</p><p>2.56</p></td><td><p>HRI</p><p>117.74</p></td></tr><tr><td>A/Korea/S0002/2019</td><td>Variant (H275Y)</td><td><p>HRI</p><p>221.58</p></td><td><p>NI</p><p>0.44</p></td><td><p>HRI</p><p>168.48</p></td></tr><tr><td rowspan="3">2018&#x02013;2019 isolates</td><td>A(H1N1)pdm09</td><td>Wild</td><td>0.1&#x02013;1.2</td><td>0.3&#x02013;0.7</td><td>0.1</td></tr><tr><td>A(H3N2)</td><td>Wild</td><td>0.1&#x02013;0.2</td><td>0.4&#x02013;0.8</td><td>0.2&#x02013;0.3</td></tr><tr><td>B</td><td>Wild</td><td>9&#x02013;16</td><td>0.7&#x02013;1.6</td><td>0.3&#x02013;0.4</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec17"><title>Antigenic characterization</title><p id="Par29">The two viruses were well inhibited by antisera from ferrets immunized with A/Michigan/45/2015 and A/Brisbane/02/2018, which are northern-hemisphere influenza A(H1N1)pdm09 isolates collected in 2018&#x02013;2019 and 2019&#x02013;2020, respectively, with less than two-fold reduced HI titer relative to homologous virus (Table&#x000a0;<xref rid="Tab7" ref-type="table">7</xref>).
<table-wrap id="Tab7"><label>Table 7</label><caption><p>Hemagglutinin inhibition assay</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Virus</th><th colspan="2">Hemagglutination inhibition titer</th></tr><tr><th colspan="2">Post-infection ferret antisera</th></tr><tr><th>A/Michigan/45/2015 Egg</th><th>A/Brisbane/02/2018 Egg</th></tr></thead><tbody><tr><td>A/Korea/S0003/2019 MDCK</td><td>640</td><td>640</td></tr><tr><td>A/Korea/S0002/2019 MDCK</td><td>320</td><td>640</td></tr><tr><td>A/Michigan/45/2015 MDCK</td><td>1280</td><td>640</td></tr><tr><td>A/Brisbane/02/2018 MDCK</td><td>640</td><td>1280</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par30">The NAI-resistant A(H1N1) virus harboring the NA gene H275Y variation was first identified in 2007, and was frequently identified worldwide in 2008&#x02013;2009 [<xref ref-type="bibr" rid="CR17">17</xref>]. However, since the 2009 A(H1N1)pdm09 pandemic, it occurred in &#x0003c;&#x02009;1% of A(H1N1)pdm09, mainly reported in patients with impaired immune systems due to immunosuppressive therapies for conditions including cancer and organ transplants [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Notably, such immunocompromised patients, when infected with influenza virus, could shed virus over a prolonged period, likely causing increased transmission. Moreover, as they shed drug-resistant virus while maintaining transmissibility, these patients may constitute a source for spreading drug-resistant influenza in the community [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par31">Although NAI-resistant virus has been rarely observed since 2000, the KCDC, through the KINRESS, identified oseltamivir and peramivir-resistant A(H1N1)pdm09 viruses harboring the H275Y NA variation in patients with acute lymphoblastic leukemia and relapsed lymphoma hospitalized in the same general hospital, with both exhibiting prolonged virus excretion. Although there was no history of the two patients occupying the same ward, we were concerned about potential NAI-resistant virus transmission. The phylogenetic analysis showed that the two isolated A(H1N1)pdm09 viruses were genetically distinct. Moreover, there were no additional reports of similar viruses in that hospital. Furthermore, van der Vries et al. [<xref ref-type="bibr" rid="CR20">20</xref>] demonstrated that A(H1N1)pdm09 virus-infected immunocompromised ferrets exhibited prolonged virus replication despite antiviral therapy, along with the H275Y substitution observed in the virus population from day 8 onwards only in ferrets that received oseltamivir. These results suggest that the H275Y substitution emerges rapidly in immunocompromised hosts under continuous antiviral selective pressure.</p><p id="Par32">Mutations suspected to represent antigenic drift in immunocompromised patients were more likely to be observed in NA than HA, albeit at a very low frequency (around 1%). However, the NA mutations did not affect antigenic properties, besides drug resistance. Although the HA N158D substitution increases the binding affinity of H5N1 avian influenza virus and human receptor (&#x003b1;2&#x02013;6-linked sialoside) [<xref ref-type="bibr" rid="CR21">21</xref>], the function of the A/Korea/S0002/2019 HA A158E substitution functionality remains unknown (but it was not involved in antigenicity in this study). Alternatively, NA and HA had different mutation spectra in swine influenza viruses collected from April to June 2019 in the United States. The antigenic drift in immunocompromised patients may allow swine influenza virus insertion to occur without pig to human transmission, ultimately reducing the efficacy of influenza vaccine escape. Nevertheless, antisera from ferrets immunized with the influenza vaccine exhibited good inhibition of A/Korea/S0002/2019 and A/Korea/S0003/2019 infection.</p></sec><sec id="Sec19"><title>Conclusions</title><p id="Par33">The NA H275Y substitution and some HA or NA substitutions in drug-resistant A(H1N1)pdm09 viruses isolated from immunocompromised patients influence both antigenicity and NAI resistance. The viruses showed highly reduced inhibition, with over 100-fold increases in the IC<sub>50</sub> for oseltamivir and peramivir, but not zanamivir. Thus, zanamivir might be an option for immunocompromised patients when oseltamivir and peramivir are not effective. These findings also indicate the necessity of monitoring for NAI-resistant viruses in outpatients visiting clinics and in-patients, particularly for immunocompromised patients (e.g., with severe acute respiratory syndromes in general hospitals). Additionally, virus characterization can facilitate the risk assessment of NAI viruses.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>KINRESS</term><def><p id="Par5">Korea Influenza and Respiratory Viruses Surveillance System</p></def></def-item><def-item><term>SARI</term><def><p id="Par6">Severe Acute Respiratory Infection</p></def></def-item><def-item><term>H</term><def><p id="Par7">Histidine</p></def></def-item><def-item><term>Y</term><def><p id="Par8">Tyrosine</p></def></def-item><def-item><term>NAIs</term><def><p id="Par9">Neuraminidase inhibitors</p></def></def-item><def-item><term>NA</term><def><p id="Par10">Neuraminidase</p></def></def-item><def-item><term>HA</term><def><p id="Par11">Hemagglutinin</p></def></def-item><def-item><term>MDCK</term><def><p id="Par12">Madin-Darby canine kidney</p></def></def-item><def-item><term>GISAID</term><def><p id="Par13">Global Initiative on Sharing All Influenza Data</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p id="Par14">Half maximal inhibitory concentration</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We thank the national influenza surveillance participating institutes.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Conception and design: Chun Kang, Yoon-Seok Chung. Acquisition of data: Namjoo Lee, Mi-Seon Kim. Analysis and interpretation: Heui Man Kim, Yoon-Seok Chung. Writing, review and revision of the manuscript: Heui Man Kim. Study supervision: Chun Kang, Yoon-Seok Chung. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by intramural funding from Korea Centers for Disease Control and Prevention (4834&#x02013;303).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data supporting the conclusions of this article are included within the article.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par34">All experimental procedures were approved by the institutional review boards of Korea Centers for Disease Control and Prevention (Ethics number: 2016-05-02-P-A).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par35">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par36">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>NJ</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Wailoo</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Nicholson</surname><given-names>KG</given-names></name></person-group><article-title>Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza a and B: systematic review and meta-analyses of randomized controlled trials</article-title><source>BMJ.</source><year>2003</year><volume>326</volume><fpage>1235</fpage><pub-id pub-id-type="doi">10.1136/bmj.326.7401.1235</pub-id><pub-id pub-id-type="pmid">12791735</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKimm-Breschkin</surname><given-names>JL</given-names></name></person-group><article-title>Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance</article-title><source>Influenza Other Respir Viruses</source><year>2013</year><volume>7</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/irv.12047</pub-id><pub-id pub-id-type="pmid">23279894</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>YA</given-names></name></person-group><article-title>Baloxavir: first global approval</article-title><source>Drugs.</source><year>2018</year><volume>78</volume><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0899-1</pub-id><pub-id pub-id-type="pmid">29623652</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moasser</surname><given-names>E</given-names></name><name><surname>Moasser</surname><given-names>A</given-names></name><name><surname>Zaraket</surname><given-names>H</given-names></name></person-group><article-title>Incidence of antiviral drug resistance markers among human influenza a viruses in the eastern Mediterranean region, 2005-2016</article-title><source>Infect Genet Evol</source><year>2019</year><volume>67</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2018.10.023</pub-id><pub-id pub-id-type="pmid">30389548</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redlberger-Fritz</surname><given-names>M</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Strassi</surname><given-names>R</given-names></name><name><surname>Popow-Kraupp</surname><given-names>T</given-names></name></person-group><article-title>Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus a (H1N1), a (H1N1) 2009, and a (H3N2) subtypes by melting point analysis</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2012</year><volume>31</volume><fpage>1593</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1007/s10096-011-1482-9</pub-id><pub-id pub-id-type="pmid">22089329</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Summary table of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI)</article-title><source>Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitors (NAI)</source><year>2018</year></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">A*STAR Bioinformatics Institute. FluSurver. <ext-link ext-link-type="uri" xlink:href="http://flusurver.bii.a-star.edu.sg/">http://flusurver.bii.a-star.edu.sg/</ext-link> Accessed 14 Mar 2016.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Fry</surname><given-names>AM</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name></person-group><article-title>Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods</article-title><source>Antivi Ther</source><year>2012</year><volume>17</volume><fpage>159</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.3851/IMP2067</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Zuccotti</surname><given-names>G</given-names></name></person-group><article-title>Prolonged shedding of multidrug-resistant influenza a virus in an immunocompromised patient</article-title><source>New Engl J Med</source><year>2003</year><volume>348</volume><fpage>867</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1056/NEJM200302273480923</pub-id><pub-id pub-id-type="pmid">12606750</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>NJ</given-names></name><name><surname>Kwon</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Development and evaluation of multiplex real-time RT-PCR assays for seasonal, pandemic a/H1pdm09 and avian a/H5 influenza viruses detection</article-title><source>J Microbiol</source><year>2013</year><volume>51</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s12275-013-2452-y</pub-id><pub-id pub-id-type="pmid">23625229</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SS</given-names></name><name><surname>Jiao</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>WZ</given-names></name><name><surname>Jiang</surname><given-names>LZ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Susceptibility of influenza a (H1N1)/pdm2009, seasonal a (H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>8488</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-08282-6</pub-id><pub-id pub-id-type="pmid">28814737</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Stech</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Perez</surname><given-names>DR</given-names></name></person-group><article-title>Universal primer set for the full-length amplification of all influenza a viruses</article-title><source>Arch Virol</source><year>2001</year><volume>146</volume><fpage>2275</fpage><lpage>2289</lpage><pub-id pub-id-type="doi">10.1007/s007050170002</pub-id><pub-id pub-id-type="pmid">11811679</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab></person-group><source>Influenza virus characterization, Summary Europe, May 2019</source><year>2019</year></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lackenby</surname><given-names>A</given-names></name><name><surname>Besselaar</surname><given-names>TG</given-names></name><name><surname>Daniels</surname><given-names>RS</given-names></name><name><surname>Fry</surname><given-names>A</given-names></name><name><surname>Gregory</surname><given-names>V</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017</article-title><source>Antivir Res</source><year>2018</year><volume>157</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.001</pub-id><pub-id pub-id-type="pmid">29981793</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">WHO GISRS Antiviral Susceptibility Expert Working Group. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016: World Health Organization; 2016.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Manual for the laboratory diagnosis and virological surveillance of influenza</source><year>2011</year></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okomo-Adhiambo</surname><given-names>M</given-names></name><name><surname>Sleeman</surname><given-names>K</given-names></name><name><surname>Ballenger</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Mishin</surname><given-names>VP</given-names></name><name><surname>Sheu</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective</article-title><source>Viruses.</source><year>2010</year><volume>2</volume><fpage>2269</fpage><lpage>2289</lpage><pub-id pub-id-type="doi">10.3390/v2102269</pub-id><pub-id pub-id-type="pmid">21994620</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memoli</surname><given-names>MJ</given-names></name><name><surname>Athota</surname><given-names>R</given-names></name><name><surname>Reed</surname><given-names>S</given-names></name><name><surname>Czajkowski</surname><given-names>L</given-names></name><name><surname>Bristol</surname><given-names>T</given-names></name><name><surname>Proudfoot</surname><given-names>K</given-names></name><etal/></person-group><article-title>The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts</article-title><source>Clin Infect Dis</source><year>2013</year><volume>58</volume><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/cid/cit725</pub-id><pub-id pub-id-type="pmid">24186906</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebbien</surname><given-names>R</given-names></name><name><surname>Pedersen</surname><given-names>SS</given-names></name><name><surname>Vorborg</surname><given-names>K</given-names></name><name><surname>Franck</surname><given-names>KT</given-names></name><name><surname>Fischer</surname><given-names>TK</given-names></name></person-group><article-title>Development of oseltamivir and zanamivir resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014</article-title><source>Euro Surveill</source><year>2017</year><volume>22</volume><fpage>30445</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.3.30445</pub-id><pub-id pub-id-type="pmid">28128091</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vries</surname><given-names>E</given-names></name><name><surname>Stittelaar</surname><given-names>KJ</given-names></name><name><surname>van Amerongen</surname><given-names>G</given-names></name><name><surname>Veldhuis Kroeze</surname><given-names>EJ</given-names></name><name><surname>de Waal</surname><given-names>L</given-names></name><name><surname>Fraaij</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets</article-title><source>PLoS Pathog</source><year>2013</year><volume>9</volume><fpage>e1003343</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003343</pub-id><pub-id pub-id-type="pmid">23717200</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>RP</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>McBride</surname><given-names>R</given-names></name><name><surname>Rigter</surname><given-names>A</given-names></name><name><surname>Hanson</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><etal/></person-group><article-title>Hemagglutinin receptor specificity and structural analyses of respiratory droplet-transmissible H5N1 viruses</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>768</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1128/JVI.02690-13</pub-id><pub-id pub-id-type="pmid">24173215</pub-id></element-citation></ref></ref-list></back></article>